In our study, FGFR1 amplification was more frequent in invasive carcinoma than in pure DCIS, and tended to be higher in invasive carcinomas than in pure DCIS in the high-grade tumors. This evidence concerns the gene FGFR1 and ductal breast carcinoma in situ.